Porsolt Increases Its Drug Discovery Service Capabilities With the Recent Expansion of Its Research Facility


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Porsolt SAS, a long established preclinical screening, efficacy, and safety CRO, has completed a significant expansion of its research facility, adding a further 5,500 sq.ft. of experimental space.

The expansion integrates Porsolt's new areas of research, cutting edge technologies, increased in vitro capabilities, and growing portfolio of preclinical models. This enhances Porsolt's ability to employ predictive tools, including cell-based models, to meet the requirements of the pharmaceutical and biotech industries and optimize drug discovery pipelines.

The additional research space comprises in vitro laboratories including cell culture, flow cytometry, histology, imaging, and analysis, that have been incorporated from Fluofarma. Porsolt has also expanded its chemistry, biochemistry, biomarker, ex-vivo capabilities, and housing capacity for in vivo studies.

"This is reflective of the consistent growth of Porsolt SAS over recent years, incorporating new areas of research and specialized expertise," commented Dr. Guillaume Froget, President and CEO of Porsolt SAS. "This enables us to continue to meet the needs of our expanding global client base, covering more stages in the drug discovery process."

Porsolt has an international reputation for expertise in physio-pathological models, customized procedures, and tailored solutions for discovering treatments in multiple disease areas, including psychiatric and neurological disorders, oncology, acute and chronic pain, inflammation, cardiac and vascular diseases, metabolic and eating disorders, dermatology, and medical devices, using in vitro cell lines and in vivo disease models in multiple species. Porsolt also provides GLP safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration, including predictive toxicology, full assessment of cardiac risk, and abuse and dependence liability.

Tags : #porsoltincreasesdrugdiscovery

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026